In this article we look at the best biotech stock to buy now according to at least one major analyst.
Vir Biotechnology is a commercial-stage immunology company that creates therapeutic products for the treatment and avoidance of dangerous infectious diseases. It creates Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand, as well as VIR-2218, VIR-3434, and VIR-1111 for the treatment of hepatitis B virus, influenza A virus prevention with VIR-2482, and human immunodeficiency virus prevention with VIR-2482.
A collaboration and license agreement with Alnylam Pharmaceuticals, Inc., a grant agreement with the Bill and Melinda Gates Foundation, a license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited, and grant agreements with the National Institutes of Health are all in place for the business.
New data on the flu vaccine will be released by the company in the upcoming year, which could boost the biotech stock’s growth. The antibody therapy, known as VIR-2482, offers users comprehensive defense against flu strains that may last the duration of a flu season.
We anticipate that VIR-2482 (intramuscularly injected monoclonal antibody for prophylaxis/prevention of influenza A) data, which will be released in mid-2023, will demonstrate significantly better efficacy than currently approved and rival pipeline-stage flu vaccines. As a result, we anticipate that consensus estimates will be materially revised upward.
Frequently Asked Questions
When did Vir Biotechnology go public?
Do any famous investors hold Vir Biotechnology Inc. stock?
Is Vir Biotechnology working on a flu vaccine that doesn’t need to guess which flu strain will be prevalent the next year?
